Hudson Bay Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Hudson Bay Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587K	Sell	160,000 -375,730	-70%	-$1.25M	﹤0.01%	988
2026 Q1	$1.64M	Buy	535,730 +110,730	+26%	+$428K	0.01%	801
2025 Q4	$1.74M	Buy	425,000 +200,000	+89%	+$991K	0.01%	732
2025 Q3	$1.1M	Buy	225,000 +75,000	+50%	+$394K	﹤0.01%	850
2025 Q2	$759K	Buy	150,000 +22,930	+18%	+$113K	﹤0.01%	1006
2025 Q1	$672K	Buy	127,070 +49,570	+64%	+$361K	﹤0.01%	988
2024 Q4	$524K	Sell	77,500 -12,500	-14%	-$84K	﹤0.01%	807
2024 Q3	$593K	Buy	90,000 +45,000	+100%	+$323K	﹤0.01%	715
2024 Q2	$338K	Buy	45,000 +15,000	+50%	+$131K	﹤0.01%	653
2024 Q1	$299K	Sell	30,000 -50,000	-63%	-$557K	﹤0.01%	594
2023 Q4	$789K	Buy	80,000 +40,000	+100%	+$285K	0.01%	536
2023 Q3	$306K	Sell	40,000 -70,000	-64%	-$698K	﹤0.01%	615
2023 Q2	$822K	Buy	+110,000	New	+$770K	0.01%	611
2022 Q3	–	Sell	-120,000	Closed	-$977K	–	1348
2022 Q2	$977K	Sell	120,000 -80,000	-40%	-$535K	0.01%	939
2022 Q1	$1.43M	Buy	+200,000	New	+$2.13M	0.02%	782

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hudson Bay Capital Management's RXRX Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Recursion Pharmaceuticals (RXRX) stake by 70% in Q2 2026, selling an estimated $1.25M and leaving 160,000 shares worth $587K. The position accounts for ﹤0.01% of the portfolio, ranked #988.

Hudson Bay Capital Management first reported a position in RXRX in Q1 2022 and has held it in 15 quarters since. The position peaked at $1.74M in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Hudson Bay Capital Management held 160,000 shares of Recursion Pharmaceuticals worth $587K as of Q2 2026.
Hudson Bay Capital Management sold 375,730 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.25M.
Recursion Pharmaceuticals made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #988 holding.
Hudson Bay Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
Hudson Bay Capital Management's Recursion Pharmaceuticals position peaked at $1.74M in Q4 2025.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.